Diabetes

InsuJet, a needle-free insulin injection system, uses jet-injection technology to deliver insulin subcutaneously in persons six years of age or older.

Three-year study shows significant and sustained weight reduction with tirzepatide and a markedly lower risk of progression from prediabetes to type 2 diabetes.

Study shows how type 2 diabetes can cause epigenetic changes leading to pancreatic cancer

Reducing progression through patient education, early detection and treatment.

Take note of this Health Canada advisory as part of our October drug news update.

Canadian company Sandoz is set to launch the very first generic semaglutide in 2026, making this costly treatment more accessible, possibly raising other issues.

More than 7,000 people with diabetes undergo a leg, foot or toe amputation every year—and the majority of those procedures could have been prevented, according to a new CIHI report.